Complete characterization of the microRNAome in a patient with acute myeloid leukemia

Ramsingh, Giridharan; Koboldt, Daniel C.; Trissal, Maria; Chiappinelli, Katherine B.; Wylie, Todd; Koul, Sunita; Chang, Li‐Wei; Nagarajan, Rakesh; Fehniger, Todd A.; Goodfellow, Paul J.; Magrini, Vincent; Wilson, Richard K.; Li, Ding; Ley, Timothy J.; Mardis, Elaine R.; Link, Daniel C.

doi:10.1182/blood-2010-05-285395

Cited by 62 publications

(53 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 In a recent study, seven new miRNAs were cloned from AML with normal karyotype. 36 These studies suggest that the number of novel miRNAs being identified is not expected to drastically increase upon additional high-throughput sequencing analyses of similar samples unless the criteria for identification of miRNAs are being altered upon new scientific insights into the structure of miRNAs. The ultimate proof for a genuine miRNA is given by the experimental evidence that a (candidate) novel miRNA precursor is being processed into a mature miRNA by an active Dicer machinery.…”

Section: Discussionmentioning

confidence: 99%

Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia

et al. 2011

View full text Add to dashboard Cite

MicroRNAs (miRNAs) relevant to acute lymphoblastic leukemia (ALL) in children are hypothesized to be largely unknown as most miRNAs have been identified in non-leukemic tissues. In order to discover these miRNAs, we applied high-throughput sequencing to pooled fractions of leukemic cells obtained from 89 pediatric cases covering seven well-defined genetic types of ALL and normal hematopoietic cells. This resulted into 78 million small RNA reads representing 554 known, 28 novel and 431 candidate novel miR genes. In all, 153 known, 16 novel and 170 candidate novel mature miRNAs and miRNA-star strands were only expressed in ALL, whereas 140 known, 2 novel and 82 candidate novel mature miRNAs and miRNA-star strands were unique to normal hematopoietic cells. Stem-loop reverse transcriptase (RT)-quantitative PCR analyses confirmed the differential expression of selected mature miRNAs in ALL types and normal cells. Expression of 14 new miRNAs inversely correlated with expression of predicted target genes (À0.49p Spearman's correlation coefficients (Rs)pÀ0.27, Pp0.05); among others, low levels of novel sol-miR-23 associated with high levels of its predicted (antiapoptotic) target BCL2 (B-cell lymphoma 2) in precursor B-ALL (Rs À0.36, P ¼ 0.007). The identification of 41000 miR genes expressed in different types of ALL forms a comprehensive repository for further functional studies that address the role of miRNAs in the biology of ALL.

show abstract

Section: Discussionmentioning

confidence: 99%

Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia

et al. 2011

View full text Add to dashboard Cite

show abstract

“…NGS is also finding application in the study of short RNAs. A comprehensive study of miRNA in acute myeloid leukemia was performed using NGS, with novel findings of differentially [69]. NGS has been clearly demonstrated to detect low-abundance HIV drug-resistant variants [70].…”

Section: Application Of Ngsmentioning

confidence: 99%

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

Banerjee¹,

2013

Curr Genet Med Rep

View full text Add to dashboard Cite

Over the last decade, the study of genomes has rapidly advanced to the point that genomic research now serves as the basis for many medical decisions and public health initiatives. Genetic variation is likely to contribute substantially to the variation in drug response observed across human populations. Genomic tools such as sequence variation and, more specifically, personal genome sequencing incorporating genome-wide association studies and nextgeneration sequences enable the precise prediction and treatment of disease. At present, DNA-based risk assessment for common complex diseases, application of molecular signatures and dose selection of therapeutic drugs are the important issues in personalized medicine. In order to make personalized medicine effective, these genomic techniques must be standardized and integrated into health systems and clinical workflow for prediction of disease incidence, genetic and environmental information to optimize the medical care and outcomes for each patient. Technology continues to lead the field of personalized medicine since the interpretation of the human genome is progressing as the cost and duration of genomic sequencing continue to decrease sharply. This review aimed at understanding the technologies that reveal how the changes that occur within the genome can alter their functions and the genomic variations that constitute individual susceptibility to diseases and responses to therapy.

show abstract

“…Other study had been reported using Illumina HiSeq 2005, Prabhakar, S.S. and colleagues to characterize the RNA expression of the kidney from diabetic rat [30]. Several studies had been reported using Illumina/Solexa Genome Analyzer, for example, Ramsingh and colleagues used 454-based sequencing to characterize the microRNAome in a patient with acute myeloid leukemia [39]. To the best of our knowledge, currently, there are only a few published data on gene expression profiling in T2DM using DNA or RNA sequencing technologies [40][41][42] in mRNA expression study.…”

Section: Next-generation Sequencingmentioning

confidence: 99%

The Current Screening Technologies of Gene Expression Profile in Diabetes Mellitus

Asmara

Haque

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Diabetes is commonly observed as a complexity and alteration of metabolic pathways through the oxidative stress and inflammations. It is a chronic condition, which has shown adverse effects and damages mechanisms. A broad study involving latest technologies has been conducted to view the alteration of gene expressions to understand the underlying of diabetes complications, a high rank of mortal disease worldwide, which demands a high cost of treatments and medications. This technology has engaged with the method of gene expression detection, which is available in the laboratory settings, includes microarray system, real-time polymerase chain reaction and next-generation sequencing. The output from gene expressions studies contributes to a better understanding of the molecular mechanism, promising a better possible gene target therapy and preventions.

show abstract

Complete characterization of the microRNAome in a patient with acute myeloid leukemia

Cited by 62 publications

References 46 publications

Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia

Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

The Current Screening Technologies of Gene Expression Profile in Diabetes Mellitus

Contact Info

Product

Resources

About